Recbio First Biotech To Brave A Hong Kong IPO In 2022

mRNA Contender For Omicron?

Chinese vaccine maker Recbio hopes an IPO in Hong Kong will bring investor attention to its mRNA COVID vaccine with potential against the Omicron variant.

Stock Exchange STAR Market — Recbio’s IPO filing notable given share falls for Hong Kong-listed biotechs • Source: Alamy

Chinese vaccine producer Jiangsu Recbio Technology Co., Ltd. is set to kick off the 2022 biotech initial public offerings on the Hong Kong Stock Exchange, as it seeks new funding for its business activities and pipeline development.

Amid surging global infections of the Omicron variant, the Taizhou, Jiangsu-based company hopes to highlight its COVID-19 vaccine candidates, including...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

16 Jun 2025

• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

13 Jun 2025

• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

13 Jun 2025

• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.